| Patent Number |
Title Of Patent |
Date Issued |
| 7622125 |
Polycistronic HIV vector constructs |
November 24, 2009 |
| The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these v |
| 7618642 |
Expression cassettes encoding modified human immunodeficiency virus type 1 subtype C envelope gl |
November 17, 2009 |
| The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described. |
| 7611708 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
November 3, 2009 |
| Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fr |
| 7608723 |
Indole and benzimidazole derivatives |
October 27, 2009 |
| The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the inventi |
| 7605246 |
Genes differentially expressed in breast cancer |
October 20, 2009 |
| A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypepti |
| 7604802 |
Method of obtaining cellular immune responses from proteins |
October 20, 2009 |
| A method for producing a cellular immune response in a vertebrate subject comprising administering to the vertebrate subject a vaccine composition comprising a protein particle antigen and a pharmaceutically acceptable excipient is disclosed. |
| 7597908 |
Use of microparticles with adsorbed antigen to stimulate immune responses |
October 6, 2009 |
| The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen. |
| 7595040 |
Deamidated interferon-.beta. |
September 29, 2009 |
| Interferon-.beta. protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-.beta., is deamidated exhibit a biological activity of native human interferon-.beta. at an increased level and do not require HA for protein stabilization. The dea |
| 7576221 |
Substituted imidazole derivatives |
August 18, 2009 |
| The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention |
| 7576176 |
Neisseria meningitidis antigens and compositions |
August 18, 2009 |
| The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics. |
| 7572628 |
Eukaryotic layered vector initiation systems |
August 11, 2009 |
| The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems. |
| 7572453 |
Chimeric alphavirus replicon particles |
August 11, 2009 |
| Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from a |
| 7566559 |
Human cyclin-dependent kinase (hPNQALRE) |
July 28, 2009 |
| A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided. |
| 7563873 |
Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same |
July 21, 2009 |
| Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the "a" determinant region of |
| 7553854 |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signali |
June 30, 2009 |
| Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic |
| 7541337 |
Methods and compositions for the treatment of peripheral artery disease |
June 2, 2009 |
| Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery |
| 7541333 |
Angiogenically effective unit dose of FGF-2 and method of use |
June 2, 2009 |
| The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acce |
| 7541142 |
Pancreatic cancer genes |
June 2, 2009 |
| The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of |
| 7538207 |
Polyepitope carrier protein |
May 26, 2009 |
| The invention relates to polyepitope carrier proteins that comprise at least five CD4+T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are par |
| 7531511 |
Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administerin |
May 12, 2009 |
| The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is |
| 7531180 |
Chimeric alphavirus replicon particles |
May 12, 2009 |
| Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from a |
| 7527925 |
Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences an |
May 5, 2009 |
| Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where |
| 7527801 |
Norovirus and Sapovirus antigens |
May 5, 2009 |
| Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and |
| 7511019 |
Method of treating coronary artery disease by administering FGF-4 |
March 31, 2009 |
| The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 .mu.g/kg to 36 .mu.g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is direc |
| 7504405 |
Mitotic kinesin inhibitors |
March 17, 2009 |
| The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of |
| 7504254 |
Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes |
March 17, 2009 |
| Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify |
| 7501244 |
Determining prognosis of colon or breast cancer by measuring TTK expression |
March 10, 2009 |
| The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be |
| 7501243 |
Detection of colon or breast cancer by measuring TTK polypeptide expression |
March 10, 2009 |
| The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be |
| 7501242 |
Detection of colon or breast cancer by measuring TTK polynucleotide expression |
March 10, 2009 |
| The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be |
| 7501134 |
Microparticles with adsorbed polypeptide-containing molecules |
March 10, 2009 |
| Microparticles with absorbed polypeptide-containing molecules formed without the use of surfactant, methods of making such microparticle compositions, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(.alpha.-hydroxy acid), a polyhydroxy butyric a |
| 7494787 |
Method for producing yeast expressed HPV types 6 and 16 capsid proteins |
February 24, 2009 |
| Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the prod |
| 7491808 |
HCV non-structural protein mutants and uses thereof |
February 17, 2009 |
| Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described. |
| 7482367 |
Substituted benzimidazoles and methods of their use |
January 27, 2009 |
| New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one se |
| 7476506 |
Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers |
January 13, 2009 |
| This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived f |
| 7470709 |
Benzimidazole quinolinones and uses thereof |
December 30, 2008 |
| Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds hav |
| 7470701 |
Substituted 2,5-heterocyclic derivatives |
December 30, 2008 |
| The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invent |
| 7462592 |
Compositions and methods for polynucleotide delivery |
December 9, 2008 |
| This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynu |
| 7456183 |
Guanidino compounds |
November 25, 2008 |
| Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH.sub.2, N, NR.sup.9, C.dbd.O, C.dbd.S, S.dbd.O, SO.sub.2, S, O, (CR.sup.6R.sup.7).sub.n, C(.dbd.O)--(CR.sup.6R.sup.7).sub.n, and C(.dbd.S)--(CR.sup.6R.sup.7).sub.n |
| 7452996 |
Substituted quinoline derivatives |
November 18, 2008 |
| The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention |
| 7449566 |
Polynucleotide encoding novel HCV non-structural polypeptide |
November 11, 2008 |
| Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host ce |
| 7445780 |
Antagonistic anti-CD40 antibodies |
November 4, 2008 |
| Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fr |
| 7442525 |
Method for expressing HIV polypeptides |
October 28, 2008 |
| Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where |
| 7439058 |
HBV/HCV virus-like particle |
October 21, 2008 |
| Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide |
| 7439041 |
Prion-specific peptide reagents |
October 21, 2008 |
| Peptide reagents that interact preferentially with the PrP.sup.sc form of the prion protein are described. Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for prions and prion-associated diseases are also des |
| 7439040 |
Protease regulator screening assay |
October 21, 2008 |
| A polypeptide containing an anchor region, a protease recognition site, and a detectable signal region can be produced recombinantly and directly attached to a solid support. The polypeptide is useful for screening protease regulators, especially protease inhibitors. |
| 7425557 |
Inhibitors of glycogen synthase kinase 3 |
September 16, 2008 |
| New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alon |
| 7425428 |
Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby |
September 16, 2008 |
| Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where |
| 7422861 |
Oligonucleotide transfection screening method |
September 9, 2008 |
| Different-sequence peptoids, including lipid- and sterol-conjugated peptoids, are found to be effective in transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids are identifi |
| 7408053 |
Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby |
August 5, 2008 |
| Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where |
| 7408023 |
Peptoids incorporating chemoselective functionalities |
August 5, 2008 |
| Molecules having potential biological activity, particularly peptoids, that are conjugated to solid phase supports, spacer groups, and/or ligation moieties, and methods of their preparation, are described. In some instances, the molecules of the invention are made entirely by solid p |
